Home Amgen says Kyprolis doubles progression-free survival vs Velcade
 

Keywords :   


Amgen says Kyprolis doubles progression-free survival vs Velcade

2015-03-02 04:09:37| Biotech - Topix.net

Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday. REUTERS: Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

Tags: survival doubles amgen progressionfree survival

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
23.11
23.11 85
23.11DANCEWITHDRAGON2 811
23.11 N5000VSE
23.11EZY POWER EDIT6
23.11RR4
23.1126.5 HG
23.11VISSLA
More »